Net Treatment Benefit (NTB)
What is Net Treatment Benefit?
Net Treatment Benefit (NTB) is a comprehensive estimator of treatment effect for randomized clinical trials. It integrates multiple clinically meaningful outcomes into a single assessment by prioritizing them according to their relative importance.
Unlike traditional analyses that evaluate efficacy and safety separately, NTB provides a holistic view of treatment performance by combining outcomes hierarchically into one patient-centric measure.
As a result, sponsors can evaluate the totality of the evidence while incorporating outcomes that matter most to patients, clinicians, regulators and payers.
Why use Net Treatment Benefit?
Patients experience treatments across multiple dimensions, including efficacy, safety, tolerability and quality of life. However, traditional clinical trial analyses often evaluate these outcomes separately, making it difficult to understand the overall treatment effect.
Net Treatment Benefit bridges this gap by integrating multiple outcomes into a single framework that reflects patient priorities and clinical relevance.
Consequently, NTB enables patient-centric clinical trial design, supports benefit-risk assessment, and provides a robust approach for evaluating the totality of the evidence.
Use Net Treatment Benefit with One2Treat Insights
One2Treat Insights enables sponsors to analyze multiple clinical outcomes simultaneously using Net Treatment Benefit and Generalized Pairwise Comparisons. The platform provides a multidimensional assessment of treatment effect, helping teams identify clinically meaningful benefits that conventional analyses may overlook.
By evaluating efficacy, safety and patient-centered outcomes together, sponsors can design more efficient trials, strengthen regulatory submissions, and support HTA and market access decisions.
Integrate patient preferences into treatment assessment
Net Treatment Benefit provides a framework for incorporating patient preferences directly into clinical trial design and treatment evaluation. By collaborating with clinicians, patients and patient advocacy groups, sponsors can prioritize outcomes according to their relative importance and formalize these preferences within a single statistical framework.
Through One2Treat Voice, these preferences can be captured systematically, enabling more patient-centric clinical trials and treatment assessments.
From clinical trial design to market access
Net Treatment Benefit enables sponsors to generate evidence that extends beyond traditional efficacy and safety analyses. By integrating prespecified, patient-relevant outcomes into the clinical trial design, sponsors can evaluate the totality of the evidence and better characterize treatment value.
This holistic assessment supports decision-making throughout the product lifecycle, from clinical development and regulatory submissions to HTA evaluations and market access. Consequently, sponsors can communicate the clinical and economic value of their treatment with greater confidence to regulators, payers, healthcare providers and patients.
Net Treatment Benefit to support dose optimization
Net Treatment Benefit can support dose optimization for FDA Project Optimus by simultaneously evaluating efficacy, safety and tolerability outcomes across dose levels. This holistic approach aligns with the principles of FDA Project Optimus and helps sponsors identify dosing strategies that maximize patient benefit.
Generalized Pairwise Comparisons (GPC)
Net Treatment Benefit is based on the statistical methodology known as Generalized Pairwise Comparisons (GPC).
GPC compares every patient in the experimental arm with every patient in the control arm according to a predefined hierarchy of outcomes. Each pair is first evaluated on the highest-priority outcome. If no difference is observed, the comparison proceeds to the next outcome, continuing until a difference is found or all outcomes have been assessed.
This approach enables efficacy, safety, tolerability and quality-of-life outcomes to be integrated into a single treatment assessment, resulting in a more comprehensive and patient-centric evaluation of treatment effect.
For example, a Net Treatment Benefit of 15% indicates that a randomly selected patient in the experimental arm has a 15% higher probability of achieving a better overall outcome than a randomly selected patient in the control arm.
To understand how to correctly interpret the Net Treatment Benefit, visit this page.
Scientific Papers
Net Treatment Benefit (NTB) is supported by a growing body of peer-reviewed research spanning statistical methodology, benefit-risk assessment, oncology, cardiovascular medicine and patient-centric clinical trial design. The following publications provide an excellent starting point for readers wishing to explore the methodology in more detail.
Foundational methodology
Buyse M. (2010). Generalized Pairwise Comparisons of Prioritized Outcomes in the Two-Sample Problem. Statistics in Medicine.
The original publication introducing Generalized Pairwise Comparisons (GPC), the statistical framework from which Net Treatment Benefit (NTB) is derived.
https://doi.org/10.1002/sim.3923
Buyse M. (2019). Generalized Pairwise Comparisons. Wiley StatsRef: Statistics Reference Online.
A comprehensive overview of the statistical principles, interpretation and practical implementation of Generalized Pairwise Comparisons.
https://doi.org/10.1002/9781118445112.stat08224
Buyse M, Saad ED, Peron J, et al. (2021). The Net Benefit of a Treatment Should Take the Correlation Between Benefits and Harms into Account. Journal of Clinical Epidemiology.
Describes how NTB simultaneously evaluates efficacy and safety outcomes to provide a more comprehensive assessment of treatment benefit-risk.
https://doi.org/10.1016/j.jclinepi.2021.03.018
Deltuvaite-Thomas V, Verbeeck J, Burzykowski T, Buyse M, et al. Generalized Pairwise Comparisons for Censored Data. Statistics in Medicine.
Explores the application of Generalized Pairwise Comparisons to time-to-event analyses commonly used in clinical trials.
https://doi.org/10.1002/sim.8788
Statistical Inference for Generalized Pairwise Comparisons. Biometrical Journal.
Presents statistical methods for estimating Net Treatment Benefit and conducting hypothesis testing using GPC.
https://doi.org/10.1002/bimj.201900354
Review article
Verbeeck J, Verwerft J, Vranckx P, et al. (2023). Generalized Pairwise Comparisons to Assess Treatment Effects. Journal of the American College of Cardiology.
A comprehensive review of the methodology, clinical interpretation and practical applications of GPC and NTB.
https://doi.org/10.1016/j.jacc.2023.06.047
Clinical applications
Peron J, Buyse M, et al. Journal of the National Cancer Institute.
Illustrates the application of Generalized Pairwise Comparisons in oncology clinical trials.
https://academic.oup.com/jnci/article/111/11/1186/5369916
The Oncologist. Net Treatment Benefit in Oncology Clinical Trials.
Discusses the growing role of NTB in oncology drug development and multidimensional endpoint assessment.
https://academic.oup.com/oncolo/article/31/4/oyag081/8524337
Oncotarget. Generalized Pairwise Comparisons in Cancer Research.
An early demonstration of the value of prioritized outcome analyses in oncology.
https://www.oncotarget.com/article/12761/text
Net Treatment Benefit as a Primary Endpoint in Oncology.
An example of NTB being used prospectively as the primary endpoint in a randomized oncology clinical trial.
https://pubmed.ncbi.nlm.nih.gov/41648032
Reference book
Buyse M, Verbeeck J, Saad ED, De Backer M, Deltuvaite-Thomas V, Molenberghs G. (Editors). Handbook of Generalized Pairwise Comparisons: Methods for Patient-Centric Analysis. CRC Press, 2025.
The definitive reference on Generalized Pairwise Comparisons and Net Treatment Benefit, covering statistical foundations, clinical applications, benefit-risk assessment, regulatory considerations and patient-centric trial design.